Palbociclib plus letrozole prolonged PFS and maintained QoL compared with placebo plus letrozole, according to results from a phase 2 trial.
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.
Broad use of PARP inhibitors to treat advanced-stage ovarian cancer would be associated with high costs compared with their biomarker-directed use.
Quality-adjusted progression-free survival (QA-PFS) represents an adjustment to PFS that incorporates patient-reported toxicity and other detrimental effects of treatment.
Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy.
Screening, preferably with primary HPV testing, should start at age 25 and continue through age 65.
Study results differ from prior research into microRNAs as predictive biomarkers.
This analysis focused on QoL end points associated with different dosing schedules for first-line carboplatin-paclitaxel in a predominantly European population with EOC.
The consensus guideline, drafted by an ASTRO-convened expert task force, offers recommendations about radiotherapy, including brachytherapy, and chemoradiation, in different stage-of-disease and treatment-strategy settings.
A proof-of-principle study confirms presence of TP53 variants ahead of diagnosis.
Preclinical studies of adavosertib indicated that the drug increased sensitization of TP53-mutated cells to chemotherapy.
The trajectory of follow-up care for women undergoing a failed endometrial biopsy has been largely unexplored.
In a whole-exome analysis, the most common mutations occurred in TP53, and mutations in other known cancer-associated genes were identified in women with HPV-negative vulvar cancer.
Women with Stage I primary mucinous epithelial ovarian carcinoma who underwent uterus-preserving surgery did not have worse survival, a retrospective study found.
This study sought to address outstanding questions regarding tumor heterogeneity in the setting of HGSOC, including its relationship with treatment response.
The researchers found that patients who received pelvic radiation had a decreased chance of live birth.
Analysis of biomarkers to predict response to pembrolizumab are ongoing.
Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.
A longer treatment-free survival interval associated with surgery may contribute to overall survival.